Clinician reviews ultrasound images and an AI-generated draft report on an ultrasound system in a healthcare setting.
16 Nov 2026

PMDA’s Draft Review Offers Manufacturers Greater Visibility into Regulatory Expectations for Generative AI-Enabled SaMD

The Japanese government and medical device manufacturers are taking a cautious stance toward software as a medical device (SaMD) utilizing generative AI, and the market adoption of SaMD utilizing generative AI, originating from Japan, is somewhat delayed. Therefore, overseas medical device manufacturers may gain an advantage in the Japanese market by understanding this document.

Generative artificial intelligence is creating new possibilities for healthcare, but it is also raising important questions for medical device manufacturers and regulators. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is taking steps to provide greater clarity around how these technologies may be evaluated when they are incorporated into SaMD.

PMDA has published draft Review Points for SaMD Utilizing Generative AI, adding generative AI to its growing collection of review points for SaMD. The material provides insight into PMDA’s thinking as manufacturers work to understand how emerging generative AI technologies may fit within Japan’s existing medical device regulatory framework.

The document should not be confused with formal regulatory guidance. It remains in draft form, and its status is below that of formal guidance documents or regulatory notices. However, the review points provide manufacturers with useful visibility into how PMDA may approach applications involving generative AI-enabled medical devices before more specific guidance or notices become available.

The objective of the document is to comprehensively summarize the review points, based on current knowledge, and to discuss regulatory principles, including evaluation methodologies and post-marketing measures.

Generative AI-enabled medical devices are under careful review, including the determination of which products should be regulated as medical devices. These review points apply to products and their claims that qualify as medical devices under the PDMA. The review points may be revised if future updates are made to medical device qualification criteria. In addition, given the rapid advancement of AI technologies, including large language models (LLMs), this document should be updated as appropriate based on emerging experience, knowledge, and regulatory developments.

Why PMDA's Review Points Matter

Japan has been steadily developing a more defined regulatory framework for SaMD. Under the PMDA, software with an intended medical purpose and significant potential risk to patients or users when it fails to function as intended can be regulated as a medical device.

PMDA has also created a dedicated Office of Software as a Medical Device and provides consultation pathways specifically for SaMD developers. These initiatives are part of a broader effort by Japanese authorities to support the practical use and commercialization of innovative software-based medical technologies.

The new generative AI material extends that effort into one of the fastest-moving areas of medical technology.

PMDA explains that its broader SaMD review-point initiative is intended to publish key considerations from its approval reviews, including test requirements and evaluation considerations. The goal is to improve manufacturers' ability to anticipate what may be expected during the approval process.

That predictability becomes especially valuable with technologies such as generative AI, where product capabilities and development approaches can evolve faster than traditional regulatory frameworks.

A Broader Push to Accelerate SaMD Innovation in Japan

The publication also needs to be viewed within Japan's wider strategy for SaMD.

Japan launched its original DASH for SaMD initiative in 2020 to promote the practical use of SaMD and establish regulatory review structures better suited to software-based medical technologies. PMDA subsequently strengthened its SaMD approval review organization in 2021.

The agency now maintains dedicated SaMD resources covering qualification, regulatory consultations, approval reviews, review points, approved products, and regulatory notifications. PMDA states that its SaMD website will continue to be updated as new information becomes available.

Generative AI is now becoming part of that evolving regulatory landscape.

The significance for manufacturers is not necessarily a new set of formal requirements. Instead, the draft provides another window into regulatory thinking at a time when companies are trying to determine how generative AI can be incorporated into medical applications while maintaining appropriate evidence of safety and effectiveness.

What Medical Device Manufacturers Should Consider

Manufacturers developing AI-enabled SaMD for Japan should pay close attention to PMDA's emerging review materials throughout development rather than waiting until an application is ready for submission.

SaMD already carries regulatory considerations distinct from software embedded within a traditional medical device. Intertek describes SaMD as standalone software serving a medical purpose, including applications involving diagnosis, patient monitoring, and treatment planning. Appropriate assurance can therefore involve areas such as risk assessment, validation and verification, cybersecurity, interoperability, and regulatory strategy.

Generative AI adds another dimension to that challenge.

Although PMDA's latest review points remain draft material rather than formal regulatory guidance, they can help development and regulatory teams better understand the issues attracting regulator attention. Manufacturers can use that information to examine their development strategy, technical evidence, risk management activities, and application documentation before entering the review process.

PMDA also offers SaMD-specific consultation pathways covering areas such as product qualification and regulatory development. For companies entering the Japanese market with innovative software-based technologies, early consideration of the appropriate regulatory pathway can be particularly valuable.

The Direction Is Becoming Clearer

Generative AI will continue challenging regulatory systems designed around more traditional medical technologies. Regulators must balance the potential benefits of innovation with their responsibility to ensure medical devices remain safe and effective.

Japan's approach provides an important example of how that balance is developing.

PMDA's publication of draft review points does not represent final guidance for generative AI medical devices. It does, however, provide manufacturers with a clearer view of the agency's developing approach and fits within Japan's broader effort to facilitate the practical use of innovative SaMD.

Medical device manufacturers considering generative AI-enabled products should monitor these developments closely and begin thinking about regulatory strategy early in development.

For companies working across multiple markets, that conversation is increasingly important. Generative AI may be evolving rapidly, but expectations around safety, performance, risk management, validation, and regulatory evidence remain fundamental to bringing medical technologies to market.

Katsutoshi Takeda headshot
Katsutoshi Takeda

Business Development Manager, Intertek Japan

With more than 16 years of experience as a medical device auditor and product certification assessor at a Notified Body, Katsutoshi Takeda has spent the past four years at Intertek providing technical support on medical device regulations. Drawing on this expertise, he can help address a wide range of questions and challenges that overseas medical device manufacturers face when entering the Japanese market.

You may be interested in...

Software as a Medical Device (SaMD)

Comprehensive solutions to help Software as a Medical Device (SaMD) developers navigate the intricate regulatory landscape, ensuring their products are both safe and effective.

Comply With Japan’s PMD Act Requirements for Medical Devices

Japan’s Pharmaceutical and Medical Device Act (PMD Act) sets stringent regulatory requirements for medical devices entering the Japanese market.

Doctor on Japan flag background. 3d illustration
27 Nov 2025

Why Now Is the Right Time to Enter Japan’s Medical Device Market

Insights into regulatory pathways, case studies, and strategies for global manufacturers entering Japan

You may be interested in...